Q-omics provides the consensus-scored MUC6 profile across patient tissues and cancer cell-line models. MUC6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MUC6 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, MUC6 RNA expression shows 15,545 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRC, and TGCT as cancer lineages where MUC6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MUC6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MUC6 survival associations across molecular data types. MUC6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MUC6 RNA expression–survival associations across cancer types. High MUC6 expression shows unfavorable associations in COAD, KIRC and UVM, but favorable associations in SKCM, READ and UCEC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for MUC6 RNA expression.
This table summarizes MUC6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MUC6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MUC6 shows lower tumor expression in KIRC, KIRP, LIHC, BRCA and KICH and higher tumor expression in COAD. The KIRC box plot shows higher MUC6 RNA expression in normal versus tumor tissue (log2 FC = −0.935, t-test p < 0.001).
This table shows molecular features associated with MUC6 in patient tissues and cancer cell lines. In patient samples, MUC6 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MUC6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
